01—Abstract
Summary
Summary of the 8-K filed March 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) reported on March 3, 2026 that its subsidiary Genevant Sciences GmbH, together with Arbutus Biopharma Corp., entered into a settlement agreement with Moderna, Inc. and ModernaTx, Inc. resolving all patent infringement litigation over Moderna's use of Genevant/Arbutus lipid nanoparticle (LNP) delivery technology in its vaccines, including Spikevax.
The settlement is valued at $2.25 billiona in total, consisting of a $950.0 million noncontingent lump sum payable by July 8, 2026, and an additional $1.3 billion contingent payment tied to the outcome of Moderna's appeal on whether 28 U.S.C. §1498 bars the infringement claims for doses sold to the U.S. Government. If the appellate court rules for Genevant/Arbutus, or Moderna does not timely appeal, the full $1.3 billion is payable; if the ruling is partial, the payment is prorated based on the affected doses. Under the settlement, Genevant/Arbutus also grants Moderna a fully paid-up, royalty-free, non-exclusive license and covenant not to sue covering certain products, and the parties exchange customary mutual releases.
Separately, Roivant's board authorized an increase in its common share repurchase program to up to $1.0 billionb (excluding fees and expenses), inclusive of the previously announced $500 million authorization. The program will be funded with available cash and cash equivalents, has no expiration date, and may be executed through tender offers, open market purchases, privately negotiated transactions, or Rule 10b5-1 trading plans. The company stated that the program may be suspended or discontinued at any time.
The press release notes that Pfizer/BioNTech litigation remains ongoing in the United States following a favorable Markman ruling issued in September 2025. The full settlement agreement will be filed as an exhibit to Roivant's Annual Report on Form 10-K for the fiscal year ending March 31, 2026, or earlier.
02—Key points
Key Highlights
- Moderna to pay Genevant/Arbutus a $950.0 million noncontingent lump sum on or before July 8, 2026
- Additional $1.3 billion contingent payment tied to the Federal Circuit's ruling on Moderna's 28 U.S.C. §1498 appeal, prorated if the ruling is partial
- Contingent payment may be repaid with interest if a Genevant/Arbutus §1498 victory is later overturned in a final nonappealable decision
- Moderna consented to entry of judgment of infringement and judgment of no invalidity on four Genevant/Arbutus patents
- Board increased share repurchase authorization to up to $1.0 billion, inclusive of the prior $500 million authorization, with no expiration date
- Repurchases to be funded with available cash and cash equivalents and may be suspended or discontinued at any time
- Pfizer/BioNTech patent litigation remains ongoing in the U.S. following a favorable September 2025 Markman ruling
03—Questions
Frequently Asked Questions
What is the total value of the Moderna settlement?
The settlement is described in the press release as a $2.25 billion global settlement, comprising a $950.0 million noncontingent payment due by July 8, 2026 and a contingent payment of up to $1.3 billion.
What determines whether Genevant/Arbutus receives the $1.3 billion contingent payment?
Payment depends on the Federal Circuit's ruling on whether 28 U.S.C. §1498 bars Genevant/Arbutus' infringement claims against Moderna. Full payment applies if the rejection of Moderna's §1498 defense is affirmed in its entirety or if Moderna does not timely appeal or voluntarily dismisses its appeal. If §1498 bars claims for some doses, the payment is prorated based on the number of doses affected.
Could Genevant/Arbutus have to return the contingent payment?
Yes. If a Genevant/Arbutus §1498 victory is later overturned in Moderna's favor in a final nonappealable decision, Genevant/Arbutus must return the contingent payment plus interest. Moderna's right to repayment ends if it does not timely appeal or if the victory is affirmed in a final nonappealable decision.
How much will Roivant be able to repurchase under its updated buyback program?
The board authorized repurchases of up to $1.0 billion (excluding fees and expenses), inclusive of the previously announced $500 million authorization. The company stated there can be no assurance of how many shares will be repurchased or at what prices.
Where can investors find the full text of the Moderna settlement agreement?
The full Settlement Agreement will be filed as an exhibit to Roivant's Annual Report on Form 10-K for the fiscal year ending March 31, 2026, or in an earlier SEC filing.
04—Continue